AU2018304380B2 - S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same - Google Patents

S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same Download PDF

Info

Publication number
AU2018304380B2
AU2018304380B2 AU2018304380A AU2018304380A AU2018304380B2 AU 2018304380 B2 AU2018304380 B2 AU 2018304380B2 AU 2018304380 A AU2018304380 A AU 2018304380A AU 2018304380 A AU2018304380 A AU 2018304380A AU 2018304380 B2 AU2018304380 B2 AU 2018304380B2
Authority
AU
Australia
Prior art keywords
composition
enantiomer
butanediol
subject
bhb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018304380A
Other languages
English (en)
Other versions
AU2018304380A1 (en
Inventor
John C. Newman
Eric Verdin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gladstone Institutes
Buck Institute for Research on Aging
University of California, San Diego
Original Assignee
Buck Inst For Research On Aging
Gladstone Institutes
Buck Institute for Research on Aging
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Inst For Research On Aging, Gladstone Institutes, Buck Institute for Research on Aging, University of California Berkeley, University of California, San Diego filed Critical Buck Inst For Research On Aging
Publication of AU2018304380A1 publication Critical patent/AU2018304380A1/en
Application granted granted Critical
Publication of AU2018304380B2 publication Critical patent/AU2018304380B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2018304380A 2017-07-21 2018-07-19 S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same Active AU2018304380B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535754P 2017-07-21 2017-07-21
US62/535,754 2017-07-21
PCT/US2018/042948 WO2019018683A1 (en) 2017-07-21 2018-07-19 BETA-HYDROXYBUTYRATE AND BUTANEDIOL ENANTIOMERS AND METHODS OF USE THEREOF

Publications (2)

Publication Number Publication Date
AU2018304380A1 AU2018304380A1 (en) 2020-01-30
AU2018304380B2 true AU2018304380B2 (en) 2022-12-15

Family

ID=65015819

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018304380A Active AU2018304380B2 (en) 2017-07-21 2018-07-19 S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same

Country Status (11)

Country Link
US (1) US11773051B2 (cg-RX-API-DMAC10.html)
EP (1) EP3654963A4 (cg-RX-API-DMAC10.html)
JP (1) JP7442095B2 (cg-RX-API-DMAC10.html)
KR (1) KR102795284B1 (cg-RX-API-DMAC10.html)
CN (1) CN111050764A (cg-RX-API-DMAC10.html)
AU (1) AU2018304380B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020001285A2 (cg-RX-API-DMAC10.html)
CA (1) CA3070453A1 (cg-RX-API-DMAC10.html)
IL (1) IL272173B2 (cg-RX-API-DMAC10.html)
MX (1) MX2020000734A (cg-RX-API-DMAC10.html)
WO (1) WO2019018683A1 (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245243B1 (en) * 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
RU2761829C2 (ru) 2016-06-07 2021-12-13 Зе Дж. Дэвид Глэдстоун Инститьютс Образуемые среднецепочечными жирными кислотами сложные эфиры бета-гидроксибутирата и бутандиола и композиции и способы на их основе
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
BR112020001285A2 (pt) 2017-07-21 2020-07-28 Buck Institute For Research On Aging s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12037317B2 (en) 2018-01-25 2024-07-16 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
ES3033482T3 (en) * 2019-02-11 2025-08-04 Axcess Global Sciences Llc S-beta-hydroxybutyrate compounds and compositions enriched with s-enantiomer
AU2020222897B2 (en) * 2019-02-11 2025-08-14 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
JP7448555B2 (ja) * 2019-02-11 2024-03-12 アクセス・グローバル・サイエンシーズ・エルエルシー ラセミベータ－ヒドロキシブチレート混合塩－酸組成物および使用方法
CN109806251A (zh) * 2019-03-04 2019-05-28 清华大学 3-羟基丁酸及其衍生物在制备抗动脉粥样硬化的产品中的应用
AU2020235643B2 (en) * 2019-03-14 2025-03-13 Augusta University Research Institute, Inc. Methods and compositions for supporting renal health
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
EP4146337B1 (de) * 2020-07-13 2024-04-17 KetoLipix Therapeutics GmbH Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren
EP4146339B1 (de) * 2020-07-13 2024-04-10 KetoLipix Therapeutics GmbH Oxobutanol-ester von polymeren carbonsäuren und deren herstellung
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN112341542B (zh) * 2021-01-08 2021-05-14 清华大学 一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用
US20220249497A1 (en) * 2021-02-05 2022-08-11 Health Via Modern Nutrition, Inc. Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance
WO2023283654A1 (en) * 2021-07-09 2023-01-12 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
US20250282707A1 (en) * 2022-04-29 2025-09-11 Buck Institute For Research On Aging Novel ketone ester compounds
EP4566598A1 (en) * 2023-12-04 2025-06-11 ZoSaLa Pharma, Inc Compositions providing sglt2i and bhb activity and methods of use to treat human disease
WO2025166164A1 (en) 2024-02-02 2025-08-07 Selah Therapeutics Limited DL- AND L-β-HYDROXYBUTYRATE AND METHODS OF USE THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123229A1 (en) * 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS42663Y1 (cg-RX-API-DMAC10.html) 1966-03-07 1967-01-17
US4263216A (en) 1978-10-20 1981-04-21 The Procter & Gamble Company Diglyceride manufacture
US4436726A (en) 1980-12-15 1984-03-13 Fujisawa Pharmaceutical Co., Ltd. N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions
BE1001209A3 (fr) * 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
EP0633319B1 (en) 1988-04-27 1999-03-17 Daicel Chemical Industries, Ltd. Process for producing optically active 1,3-butanediol
JP2578658B2 (ja) 1989-02-21 1997-02-05 チッソ株式会社 光学活性化合物及びその製造法
US5008126A (en) 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
IT1240760B (it) 1990-02-12 1993-12-17 Sigma Tau Ind Farmaceuti Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma.
DE69205560T2 (de) 1992-01-08 1996-04-11 Nestle Sa Kosmetische und dermatologische Zusammensetzung, die Dioldiester enthält.
DE19703471A1 (de) 1997-01-31 1998-08-06 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Butylenglycoldiestern
CN1315473C (zh) 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
EP1052240B1 (en) 1999-05-11 2003-03-19 Dow AgroSciences LLC Process for the preparation of substituted 3-hydroxybutyrate esters
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
WO2002030884A2 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
EP1528053A1 (en) 2003-10-31 2005-05-04 Lonza Ag Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates
JP2006063001A (ja) 2004-08-25 2006-03-09 Takasago Internatl Corp 光学活性β−ブチロラクトンの製造方法
CN105175257A (zh) 2006-02-10 2015-12-23 杜邦塔特和莱尔生物产品有限责任公司 包括生物学基1,3-丙二醇的单酯和二酯的组合物
JP5054418B2 (ja) 2007-04-23 2012-10-24 ポーラ化成工業株式会社 クレンジング用の化粧料に好適な皮膚外用剤
ES2655367T3 (es) * 2008-08-21 2018-02-19 Oxford University Innovation Limited Bebida que comprende éster de hidroxibutirato y uso médico de la misma
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
CN102449157B (zh) * 2009-04-16 2015-06-03 伊希斯创新有限公司 使用短乳杆菌醇脱氢酶通过酶促对映选择性还原来制备(3r)-羟丁基(3r)-羟基丁酸酯的方法
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
JP5947788B2 (ja) 2010-04-28 2016-07-06 アーケマ・インコーポレイテッド ハロゲン化オレフィン発泡剤を含むポリウレタンポリオールブレンド物の安定性を改良する方法
KR101243240B1 (ko) 2010-07-19 2013-04-04 (주)에이씨티 신규 알킬디올 유도체화합물 및 이를 포함하는 미백용 피부외용제조성물
CN103360243B (zh) 2012-03-31 2015-06-17 中国石油化工股份有限公司 一种1,3-二酰氧基丙烷类化合物的制备方法
KR101291441B1 (ko) 2012-05-01 2013-07-30 코니카 미놀타 어드밴스드 레이어즈 인코포레이티드 위상차 필름, 편광판의 제조 방법 및 액정 표시 장치
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
JP6521967B2 (ja) 2013-08-06 2019-05-29 イマーゴ バイオサイエンシーズ インコーポレイテッド 疾患の治療のためのｋｄｍ１ａ阻害剤
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
RU2761829C2 (ru) 2016-06-07 2021-12-13 Зе Дж. Дэвид Глэдстоун Инститьютс Образуемые среднецепочечными жирными кислотами сложные эфиры бета-гидроксибутирата и бутандиола и композиции и способы на их основе
BR112020001285A2 (pt) 2017-07-21 2020-07-28 Buck Institute For Research On Aging s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização
US12037317B2 (en) 2018-01-25 2024-07-16 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20190262415A1 (en) 2018-02-26 2019-08-29 Ketologie LLC Supplement for inducing and sustaining nutritional ketosis
WO2021211609A1 (en) 2020-04-16 2021-10-21 Buck Institute For Research On Aging Treatment of viral pathologies with exogenous ketones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123229A1 (en) * 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders

Also Published As

Publication number Publication date
EP3654963A4 (en) 2021-04-14
KR102795284B1 (ko) 2025-04-11
IL272173B2 (en) 2025-06-01
JP2020527583A (ja) 2020-09-10
CA3070453A1 (en) 2019-01-24
KR20200029547A (ko) 2020-03-18
WO2019018683A1 (en) 2019-01-24
BR112020001285A2 (pt) 2020-07-28
CN111050764A (zh) 2020-04-21
US11773051B2 (en) 2023-10-03
JP7442095B2 (ja) 2024-03-04
IL272173A (en) 2020-03-31
EP3654963A1 (en) 2020-05-27
US20200140371A1 (en) 2020-05-07
IL272173B1 (en) 2025-02-01
MX2020000734A (es) 2020-07-29
AU2018304380A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US11773051B2 (en) S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
US20240317671A1 (en) Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US20080009467A1 (en) Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
CA2678806C (en) Treating adhd and other diseases involving inflammation
CN101842103A (zh) 用于脑部健康的单位剂量
KR101734152B1 (ko) 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
US20190151275A1 (en) Composition for treatment of neurodegenerative disease
ZA200700395B (en) Novel formulation for L-tryptophane comprising carbidopa/benserazide
US20240122890A1 (en) Use of exogenous ketone esters to induce weight loss in mammals
US20250282707A1 (en) Novel ketone ester compounds
US20210322465A1 (en) Magnesium-containing formulation and uses thereof
US20240180891A1 (en) Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies
US20250161270A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
WO2024171073A1 (en) Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with n-acylethanolamines, and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)